Dr. Raymond Comenzo, MD, Director of the Myeloma and Amyloid Program and a world-renowned hematologist/oncologist at Tufts Medical Center in Boston discuss myeloma and amyloid. Diagnosing Rare Cancers
Amyloidosis expert – Dr. Raymond Comenzo, Director, Blood Bank and Stem Cell Processing Laboratory and Director, John C. Davis Myeloma and Amyloid Program at Tufts Medical Center was recently featured in a "The Balancing Act" interview to describe the symptoms and risk factors of AL amyloidosis.
Into and Beyond Clonal Plasma Cells in AL Amyloidosis
Presentation by Dr. Raymond Comenzo on the history and future of AL management at the XV International Symposium on Amyloidosis.
Recorded in Uppsala, Sweden on July 5, 2016
Newly Diagnosed Myleoma
Dr. Raymond Comenzo, Hematologist and Director of the John C. Davis Myeloma and Amyloid Program at Tufts Medical Center, talks about newly diagnosed multiple myeloma: what you can expect, what needs to be done, and resources to help you through the process. The video was recorded on 10/2/15 at Tufts Medical Center.
Treatment for Newly Diagnosed Multiple Myeloma
An introduction to initial therapy for newly diagnosed multiple myeloma by Dr. Raymond Comenzo, Hematologist and Director of the John C. Davis Myeloma and Amyloid Program at Tufts Medical Center: an overview of different therapeutic agents, tracking your response, and what questions you should ask your hematologist. The video was recorded on 10/6/15 at Tufts Medical Center.
Autologous Stem Cell Transplant for Multiple Myeloma
Autologous Stem Cell Transplant is an effective therapy option often used in multiple myeloma treatment. Dr. Raymond Comenzo, hematologist and director of the Davis Program, gives an overview of the screening process, collection of stem cells, and what to expect during your hospital stay. The video was recorded on 12/14/2015 at Tufts Medical Center.
A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early
Screening smoldering multiple myeloma (SMM) patients to determine their risk of progressing to other diseases is an important next step in SMM management. In this video, Dr. Comenzo explains the importance of screening SMM patients for their risk of developing AL amyloidosis, which is often misdiagnosed or overlooked. Tufts Medical Center is addressing this issue with our open clinical trial, “A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early.” This trial is open to SMM patients with lambda light chain involvement in the United States. More information on this trial can be found at
https://clinicaltrials.gov/ct2/show/NCT02741999. This video was recorded on 4/19/2016 at Tufts Medical Center.